Nikkilä Rayan, Hirvonen Elli, Pitkäniemi Janne, Räsänen Jari V, Malila Nea K, Mäkitie Antti
Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.
Department of Otorhinolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Clin Epidemiol. 2024 Jul 22;16:475-485. doi: 10.2147/CLEP.S471802. eCollection 2024.
The occurrence of a second primary cancer (SPC) after primary esophageal carcinoma (EC) or gastric cardia carcinoma(GCC) is well acknowledged. However, previous research on the risk of SPC among these patients has been predominantly conducted in Asian countries. Yet, notable population-dependent variation in histological types and risk profiles exists. This register-based study assesses the histology-specific risk of SPC among individuals initially diagnosed with a first primary EC or GCC.
We obtained data on 7197 patients diagnosed with EC/GCC in Finland between 1980 and 2022 from the Finnish Cancer Registry. Standardized incidence ratios (SIR) of SPC were subsequently calculated relatively to the cancer risk of the general population.
The average and median follow-up times were 2.8 years and 10.5 months. Adenocarcinomas and squamous cell carcinomas comprised 57.8% (n = 4165) and 36.6% (n = 2631) of all cases, respectively. An increased SIR was noted among EC/GCC patients after 15-20 years of follow-up (SIR 1.49, 95% CI: 1.01-2.11). Among adenocarcinoma patients, an increased SIR for SPCs of the digestive organs was seen in the 40-54-year-old group (SIR 9.86, 95% CI: 3.62-21.45). Squamous cell carcinoma patients displayed increased SIRs for cancer of the mouth/pharynx (SIR 3.20, 95% CI: 1.17-6.95) and respiratory organs (1.77, 1.07-2.76).
Healthcare professionals should be aware of the increased risk of SPCs occurring in the mouth/pharynx, respiratory and digestive organs in survivors of EC/GCC. Patients should be advised about this risk and remain alert for symptoms, even beyond the standard 5-year follow-up period.
原发性食管癌(EC)或贲门癌(GCC)后发生第二原发性癌症(SPC)已得到充分认可。然而,此前关于这些患者发生SPC风险的研究主要在亚洲国家进行。然而,组织学类型和风险特征存在显著的人群依赖性差异。这项基于登记处的研究评估了最初被诊断为原发性EC或GCC的个体中SPC的组织学特异性风险。
我们从芬兰癌症登记处获得了1980年至2022年期间在芬兰诊断为EC/GCC的7197例患者的数据。随后计算了SPC的标准化发病比(SIR)相对于一般人群的癌症风险。
平均随访时间和中位随访时间分别为2.8年和10.5个月。腺癌和鳞状细胞癌分别占所有病例的57.8%(n = 4165)和36.6%(n = 2631)。随访15 - 20年后,EC/GCC患者的SIR升高(SIR 1.49,95% CI:1.01 - 2.11)。在腺癌患者中,40 - 54岁组消化器官SPC的SIR升高(SIR 9.86,95% CI:3.62 - 21.45)。鳞状细胞癌患者口腔/咽癌(SIR 3.20,95% CI:1.17 - 6.95)和呼吸器官癌(1.77,1.07 - 2.76)的SIR升高。
医疗保健专业人员应意识到EC/GCC幸存者口腔/咽、呼吸和消化器官发生SPC的风险增加。应告知患者这一风险,即使在标准的5年随访期之后,也应保持对症状的警惕。